Q2 Earnings Forecast for Genmab A/S Issued By HC Wainwright

Genmab A/S (NASDAQ:GMAB) – Equities researchers at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Genmab A/S in a note issued to investors on Wednesday, April 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.41 per share for the quarter, up from their previous estimate of $0.39. HC Wainwright currently has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q3 2025 earnings at $0.44 EPS, Q4 2025 earnings at $0.45 EPS, FY2025 earnings at $1.48 EPS and FY2026 earnings at $1.72 EPS.

Several other equities analysts also recently commented on GMAB. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Sanford C. Bernstein lowered Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Finally, Truist Financial cut their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $39.17.

Genmab A/S Stock Up 4.4 %

Shares of GMAB opened at $18.81 on Thursday. The company has a market cap of $12.45 billion, a P/E ratio of 10.81, a PEG ratio of 2.65 and a beta of 1.07. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.41. The firm’s 50 day moving average price is $20.48 and its 200 day moving average price is $21.31.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GMAB. Deep Track Capital LP acquired a new position in shares of Genmab A/S in the 4th quarter valued at $41,740,000. Brandywine Global Investment Management LLC acquired a new position in Genmab A/S in the fourth quarter valued at $33,804,000. Two Sigma Advisers LP boosted its stake in Genmab A/S by 168.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock valued at $34,509,000 after acquiring an additional 1,038,400 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after purchasing an additional 938,455 shares during the last quarter. Finally, Marshall Wace LLP increased its position in shares of Genmab A/S by 162.2% during the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock worth $23,422,000 after purchasing an additional 694,243 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.